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A highly effective malaria vaccine is a major goal of glo-
bal health research and will likely require a multi-stage
product. Oxford researchers are developing the concept
of a highly effective multi-stage P. falciparum vaccine to
the point of proof-of-concept phase II testing in Europe,
prior to trials in malaria-endemic areas.
Remarkable recent advances in vaccine design for all
four stages of the P. falciparum parasite’s life-cycle
allow testing of a multi-stage multi-component vaccine
for the first time, with strong chances of success. These
advances are i) the availability of a new vectored prime-
boost vaccination regime based on the chimpanzee ade-
novirus technology that has been found to induce
exceptionally potent CD8+ T cell responses and high
titre antibodies against multiple malaria antigens; ii) the
development of an improved virus-like particle (VLP)
version of the leading partially protective RTS,S sporo-
zoite vaccine candidate, termed R21, that lacks the
excess of HBsAg in RTS,S; iii) the identification, using a
vector technology screen, of the blood-stage antigen
RH5 as the first antigen to induce potent strain-trans-
cending neutralization of blood-stage parasites in in
vitro growth inhibition assays; and iv) the demonstration
that antibodies against a mosquito-stage antigens that
induce 100% transmission blocking against field isolates
of P. falciparum in Africa are inducible by a new nano-
particle vaccine candidate.
In parallel similar approaches using vectors and VLPs
are underway to target the pre-erythrocytic stages of P.
vivax, including the hypnozoite, and a phase I trial of
the vivax blood-stage vaccine candidate, PvRII, is near-
ing completion.
We are aiming to undertake phase I/II clinical trials to
assess the P. falciparum pre-erythrocytic, blood-stage
and mosquito-stage components individually, and then
together, using state-of-the art immunomonitoring, key
functional assays of vaccine-induced immunogenicity,
and sporozoite and blood-stage parasite challenges to
measure efficacy prior to field testing. An update on this
programme will be presented. A viral vectored prime-
boost regime has recently shown high efficacy against
malaria infection in East Africa and the first combina-
tion trial of RTS,S/AS01 with these vectors has been
completed.
The prospects for achieving high efficacy with such
combination approaches now appear very good.
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